Literature DB >> 6393677

Human and porcine insulins are equally effective in the regulation of glucose kinetics of diabetic patients during exercise.

V A Koivisto, R Pelkonen, E A Nikkilä, L G Heding.   

Abstract

The rate of hepatic glucose production (Ra) and peripheral utilization (Rd) was determined in 8 insulin-dependent diabetic subjects in basal state and during 40 min cycle ergometric exercise. The patients were treated with continuous sc infusion of either semisynthetic human or porcine (Actrapid) insulin. Basal rate of glucose production was comparable during human (2.29 +/- 0.19 mg/kg/min) and porcine (2.18 +/- 0.12 mg/kg/min) insulin therapy. In response to exercise, Ra rose 30 to 40% (P less than 0.05), to 2.85 +/- 0.35 vs 3.18 +/- 0.42 mg/kg/min, similarly during both studies. The peak rise in Rd (to 3.20 +/- 0.32 during human vs 3.78 +/- 0.44 mg/kg/min during porcine insulin) was comparable in both groups and not significantly different from the rise in Ra. Consequently, blood glucose levels remained unchanged. During the exercise tests, the metabolic conditions were stable and comparable in both studies, as indicated by similar levels of blood glucose, plasma free insulin HbA1, serum lipids and insulin binding to erythrocytes. In conclusion, semisynthetic human insulin is equally effective as porcine insulin in regulating glucose kinetics in the basal state and during exercise.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6393677     DOI: 10.1530/acta.0.1070500

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  2 in total

Review 1.  Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

2.  Abdominal adiposity and daily step counts as determinants of glycemic control in a cohort of patients with type 2 diabetes mellitus.

Authors:  P Manjoo; L Joseph; K Dasgupta
Journal:  Nutr Diabetes       Date:  2012-01-16       Impact factor: 5.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.